Lung Cancer · 2020 · 20 citations · 37 references
MedicineOncologyPharmacologyMolecular OncologyNeoplasiaOncogenesChemotherapy ResistanceOncogenic Signaling PathwaysReceptor Tyrosine Kinase OncogenesTargeted Cancer TherapyTherapeutic ResistanceTyrosine Kinase InhibitorsAlk InhibitionAlk Point MutationsAnaplastic Lymphoma Kinase InhibitionAnaplastic Lymphoma Kinase InhibitorsKinase Inhibitor ResistanceLung AdenocarcinomaProtein Kinase InhibitorsResistance To Tyrosine Kinase Inhibitors
37
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Manabu Soda, Young Lim Choi, Munehiro Enomoto et al. · Nature · 2007 · 5.4K citations
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Eunice L. Kwak, Yung‐Jue Bang, D. Ross Camidge et al. · New England Journal of Medicine · 2010 · 4.5K citations
Medicine, Oncology, Pharmacology +14
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
Alice T. Shaw, Dong‐Wan Kim, Kazuhiko Nakagawa et al. · New England Journal of Medicine · 2013 · 3.4K citations · Full text
Medicine, Oncology, Pharmacology +15
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
Bhupinder Mann, John R. Johnson, Martin H. Cohen et al. · The Oncologist · 2007 · 1.4K citations · Full text
Medicine, Oncology, Pharmacotherapy +14
Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
Ryohei Katayama, Alice T. Shaw, Tahsin Khan et al. · Science Translational Medicine · 2012 · 1.3K citations
Medicine, Oncology, Pharmacology +17